Zacks2d agoneutral
JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania StudyJ&J's Caplyta shows rapid and significant improvement in bipolar mania symptoms in a pivotal phase III study.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
141last 24h
873last 7d
146● bullish (7d)
98● bearish (7d)
214publishers
Simply Wall St.2d agoneutral
What Johnson & Johnson (JNJ)'s Bipolar I Mania Data for CAPLYTA Means For ShareholdersJohnson & Johnson recently reported positive topline Phase 3 results for CAPLYTA (lumateperone) in adults with bipolar I disorder experiencing manic episodes, showing rapid and statistically significant symptom reduction versus placebo, while also highlighting progress across its broader neuropsychiatry portfolio. The data suggest CAPLYTA could potentially treat both depressive and acute manic episodes in bipolar I disorder, meaningfully broadening its clinical role if future regulatory...
Clinical Trials Arena2d agobullish
J&J’s Intra-Cellular buy continues to bear fruit with Caplyta bipolar winJ&J acquired Intra-Cellular in 2025 for $14.6bn, making it the largest pharma M&A deal in 2025.
Investor's Business Daily15d agoneutral
IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.
24/7 Wall St.35d agoneutral
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPOSeaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third.
PA Media: Money52d agoneutral
Stocks mixed as AstraZeneca merger talk dents FTSE 100The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
MT Newswires55d agoneutral
AbbVie Trims Full-Year Profit Outlook Due to Apogee AcquisitionAbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution
Insider Monkey62d agoneutral
Jim Cramer Says Kimberly-Clark’s Acquisition of Kenvue Creates a High-Margin PowerhouseOn Tuesday’s episode of CNBC’s Mad Money, Jim Cramer highlighted Kimberly-Clark Corporation (NYSE:KMB) as a defensive holding for investors looking to lock in profits from high-flying technology stocks and reallocate into lower-risk value plays. After years of sluggish price action, Cramer noted that the consumer giant has finally established a stable bottom, anchored by a […]
Zacks107d agoneutral
J&J to Expand Cancer Pipeline With $1B Firefly Bio AcquisitionJNJ is set to acquire Firefly Bio for $1 billion in cash, adding its Firelink DAC platform and advancing efforts in KRAS-driven cancer treatments.
Quartz108d agoneutral
Johnson & Johnson acquires Firefly Bio for $1 billionThe deal targets KRAS-driven tumors, which J&J says have limited treatment options and survival measured in months